

Information related to Meningococcal Vaccines

There are several vaccines available that provide immunization for meningococcal meningitis.

- Monovalent vaccines provide protection against the meningococcal serotype C bacteria. Trade names of the monovalent vaccine include:
 - Neisvac-C®
 - Menjugate®
 - Meningitec®
- Quadrivalent meningococcal vaccines provide protection against serotypes A, C, Y and W-135. Trade names of the quadrivalent vaccine include:
 - Menactra®
 - Menveo®
 - Nimenrix®
- A further, newly licensed vaccine, provides protection against serotype B meningococcal bacteria, called Bexsero®. Currently not recommended for routine immunization as part of a publicly funded program. Further details please see the [National Advisory Committee on Immunization statement](#).
- Publicly funded monovalent C vaccine is provided in Nova Scotia for children at 12 months of age, and grade seven students
- As of the 2015-16 school year, grade seven students will be provided with quadrivalent meningococcal vaccine rather than the monovalent meningococcal C vaccine
- Publicly funded meningococcal vaccine (monovalent C and quadrivalent) are available in Nova Scotia for individuals with high risk conditions
- Meningococcal vaccines may also be publicly funded for close contacts of meningococcal meningitis cases and in outbreak situations determined by Public Health
- Vaccines that are not publicly funded are available for purchase privately. Individuals who wish to obtain non publicly funded vaccines should discuss this with a health care provider
- Currently there is no issue with supply, however given some pharmacies may not routinely stock these vaccines it may take several days for them to bring this vaccine in from the distributor